BioCryst Launches ORLADEYO® in Ireland
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has made a significant advancement by announcing the launch of ORLADEYO® (berotralstat) in Ireland. This development follows a favorable recommendation from the Health Services Executive (HSE) for ORLADEYO's use in preventing recurrent attacks of hereditary angioedema (HAE) in patients aged 12 and older. With this approval, Irish patients will now have access to the first oral, once-daily therapeutic option specifically aimed at reducing the frequency of HAE attacks.
Importance of HAE Treatment Accessibility
According to Charlie Gayer, the chief commercial officer of BioCryst, this recommendation serves to broaden the accessibility of modern prophylactic treatments. It not only provides more options for physicians but is expected to significantly enhance the quality of life for HAE patients in the region. This accessibility reflects an ongoing commitment to offering innovative healthcare solutions that cater to patients' needs.
Overview of ORLADEYO®
ORLADEYO® (berotralstat) stands out as the first oral therapy explicitly designed to prevent hereditary angioedema attacks in both adults and pediatric patients who are at least 12 years old. Administering just one capsule daily can help decrease the activity of plasma kallikrein, thereby preventing these distressing symptoms.
Clinical Indications and Safety Precautions
ORLADEYO is a plasma kallikrein inhibitor that is indicated for prophylaxis against HAE attacks. However, it is essential to note that it has not been established as a treatment for acute HAE attacks. Physicians should exercise caution; doses exceeding the recommended amount of 150 mg daily are not advised due to associated risks of QT prolongation.
Common adverse reactions reported include abdominal pain, diarrhea, and vomiting—effects that could lead to increased healthcare visits and possible interruptions to treatment. Patients with moderate to severe liver impairment may have a recommended dosage adjustment to ensure safety and efficacy.
BioCryst's Growth and Commitment
BioCryst has established itself as a crucial player in the biotechnology sector, focusing on the development of first-in-class therapeutics. The company utilizes advanced structure-guided drug design techniques to create effective treatments for rare diseases. ORLADEYO is a testament to their success in commercializing innovative solutions that address unmet medical needs.
Future Directions for BioCryst
As BioCryst continues to expand its market reach, the company is committed to ensuring that healthcare providers and patients are well-informed about the benefits and limitations of ORLADEYO. Active monitoring of patient outcomes and side effects will remain a priority as they gather essential data to support ongoing treatment development.
Frequently Asked Questions
What is ORLADEYO used for?
ORLADEYO is an oral medication used to prevent recurrent attacks of hereditary angioedema in patients aged 12 years and older.
How does ORLADEYO work?
ORLADEYO works by decreasing the activity of plasma kallikrein, which helps to prevent HAE attacks.
Are there any side effects associated with ORLADEYO?
Common side effects include abdominal pain, diarrhea, and vomiting. Monitoring for these effects is essential to manage them effectively.
Who should not use ORLADEYO?
ORLADEYO should not be used to treat acute HAE attacks and is contraindicated for patients with certain liver impairments or those on specific medications that may interact adversely.
How can I report side effects from ORLADEYO?
Reports of adverse reactions can be made to BioCryst Pharmaceuticals or the relevant health authority using online reporting systems.
